Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. BMJ Publishing Group.
Chicago Style (17th ed.) CitationCorrection: Apatinib Plus Camrelizumab (anti-PD1 Therapy, SHR-1210) for Advanced Osteosarcoma (APFAO) Progressing After Chemotherapy: A Single-arm, Open-label, Phase 2 Trial. BMJ Publishing Group.
MLA (9th ed.) CitationCorrection: Apatinib Plus Camrelizumab (anti-PD1 Therapy, SHR-1210) for Advanced Osteosarcoma (APFAO) Progressing After Chemotherapy: A Single-arm, Open-label, Phase 2 Trial. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.